Recent Finacing
Recent Raise
ExcelMab develops tumor‑targeting bispecific antibodies for breast, gastric cancer and CLL using its ExMab dual‑antibody platform that enables low‑immunogenicity, high‑yield, easily purified heterodimeric molecules.
Focus Areas
Recent Investors
Funding round
Investors
See the team members at ExcelMab.
